QQQ   437.99 (-1.66%)
AAPL   175.14 (+0.06%)
MSFT   421.23 (-1.57%)
META   513.75 (-1.80%)
GOOGL   157.87 (-0.97%)
AMZN   185.79 (-1.72%)
TSLA   171.09 (-2.01%)
NVDA   887.98 (-2.01%)
AMD   162.70 (-4.57%)
NIO   4.11 (-7.85%)
BABA   72.05 (-3.74%)
T   16.34 (-0.49%)
F   12.60 (-3.37%)
MU   122.54 (-3.90%)
GE   154.27 (-1.99%)
CGC   7.96 (-2.33%)
DIS   114.28 (-2.45%)
AMC   2.69 (-3.93%)
PFE   25.91 (-1.63%)
PYPL   64.82 (-1.49%)
XOM   121.55 (-0.20%)
QQQ   437.99 (-1.66%)
AAPL   175.14 (+0.06%)
MSFT   421.23 (-1.57%)
META   513.75 (-1.80%)
GOOGL   157.87 (-0.97%)
AMZN   185.79 (-1.72%)
TSLA   171.09 (-2.01%)
NVDA   887.98 (-2.01%)
AMD   162.70 (-4.57%)
NIO   4.11 (-7.85%)
BABA   72.05 (-3.74%)
T   16.34 (-0.49%)
F   12.60 (-3.37%)
MU   122.54 (-3.90%)
GE   154.27 (-1.99%)
CGC   7.96 (-2.33%)
DIS   114.28 (-2.45%)
AMC   2.69 (-3.93%)
PFE   25.91 (-1.63%)
PYPL   64.82 (-1.49%)
XOM   121.55 (-0.20%)
QQQ   437.99 (-1.66%)
AAPL   175.14 (+0.06%)
MSFT   421.23 (-1.57%)
META   513.75 (-1.80%)
GOOGL   157.87 (-0.97%)
AMZN   185.79 (-1.72%)
TSLA   171.09 (-2.01%)
NVDA   887.98 (-2.01%)
AMD   162.70 (-4.57%)
NIO   4.11 (-7.85%)
BABA   72.05 (-3.74%)
T   16.34 (-0.49%)
F   12.60 (-3.37%)
MU   122.54 (-3.90%)
GE   154.27 (-1.99%)
CGC   7.96 (-2.33%)
DIS   114.28 (-2.45%)
AMC   2.69 (-3.93%)
PFE   25.91 (-1.63%)
PYPL   64.82 (-1.49%)
XOM   121.55 (-0.20%)
QQQ   437.99 (-1.66%)
AAPL   175.14 (+0.06%)
MSFT   421.23 (-1.57%)
META   513.75 (-1.80%)
GOOGL   157.87 (-0.97%)
AMZN   185.79 (-1.72%)
TSLA   171.09 (-2.01%)
NVDA   887.98 (-2.01%)
AMD   162.70 (-4.57%)
NIO   4.11 (-7.85%)
BABA   72.05 (-3.74%)
T   16.34 (-0.49%)
F   12.60 (-3.37%)
MU   122.54 (-3.90%)
GE   154.27 (-1.99%)
CGC   7.96 (-2.33%)
DIS   114.28 (-2.45%)
AMC   2.69 (-3.93%)
PFE   25.91 (-1.63%)
PYPL   64.82 (-1.49%)
XOM   121.55 (-0.20%)

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

$8.59
-0.19 (-2.16%)
(As of 01:02 PM ET)

Voyager Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$19.33
125.07% Upside
High Forecast$30.00
Average Forecast$19.33
Low Forecast$14.00
TypeCurrent Forecast
4/13/23 to 4/12/24
1 Month Ago
3/14/23 to 3/13/24
3 Months Ago
1/13/23 to 1/13/24
1 Year Ago
4/13/22 to 4/13/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.33$16.00$16.00$14.00
Predicted Upside125.07% Upside64.06% Upside61.18% Upside76.99% Upside
Get Voyager Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

VYGR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VYGR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Voyager Therapeutics Stock vs. The Competition

TypeVoyager TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside120.20% Upside1,081.71% Upside8.31% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/26/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$22.00+137.58%
3/19/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00+230.03%
3/7/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+73.35%
1/2/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$9.00 ➝ $14.00+35.14%
9/18/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Livshits
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
8/7/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$16.00+84.76%
5/10/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.00+67.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:19 PM ET.

VYGR Price Target - Frequently Asked Questions

What is Voyager Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Voyager Therapeutics stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for VYGR. The average twelve-month price prediction for Voyager Therapeutics is $19.33 with a high price target of $30.00 and a low price target of $14.00. Learn more on VYGR's analyst rating history.

Do Wall Street analysts like Voyager Therapeutics more than its competitors?

Analysts like Voyager Therapeutics more than other Medical companies. The consensus rating score for Voyager Therapeutics is 2.86 while the average consensus rating score for medical companies is 2.68. Learn more on how VYGR compares to other companies.

Does Voyager Therapeutics's stock price have much upside?

According to analysts, Voyager Therapeutics's stock has a predicted upside of 102.23% based on their 12-month stock forecasts.

What analysts cover Voyager Therapeutics?

Voyager Therapeutics has been rated by Citigroup, Guggenheim, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:VYGR) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners